NewsResearch
DESTINY-Lung01: What the Lung Cancer Trial Found
DESTINY-Lung01 tested trastuzumab deruxtecan in HER2-mutant lung cancer, a group with no targeted option at the time. Just over half of tumours shrank — and a quarter of patients developed drug-related lung inflammation.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
A HER2 drug in a lung cancer that had none
HER2 is best known as a breast cancer target. A small share of lung cancers carry a mutation in the same gene, and when this trial started no HER2-directed treatment had been approved for them.
Trastuzumab deruxtecan is not a plain antibody. It is an antibody with a chemotherapy payload chemically tied to it. The antibody finds HER2 on the cancer cell, and the cell pulls the whole package inside, where the payload is released. The design is meant to concentrate a toxic drug where it is wanted.
Who took part
| Field | Detail |
|---|---|
| Trial | DESTINY-Lung01 |
| Identifier | NCT03505710 |
| Phase | Phase 2 |
| Design | Multicentre, international, single-arm |
| Cancer type | Metastatic HER2-mutant non-small-cell lung cancer |
| Treatment | Trastuzumab deruxtecan, given by infusion at a weight-based dose |
| Primary endpoint | Objective response, judged by independent central review |
91 people enrolled. Every one had metastatic HER2-mutant lung cancer that standard treatment had stopped controlling. There was no comparison group. Follow-up ran to a median of 13.1 months, with individual patients followed for anywhere from three weeks to nearly two and a half years.
How often tumours shrank
Independent reviewers confirmed a response in 55% of patients (95% CI 44 to 65). Responses lasted a median of 9.3 months (95% CI 5.7 to 14.7).
Median time before the cancer grew again was 8.2 months (95% CI 6.0 to 11.9). Median overall survival was 17.8 months (95% CI 13.8 to 22.1).
Responses appeared across different HER2 mutation types. They also appeared in people whose tumours had no detectable HER2 protein and no extra copies of the gene — which suggests the mutation itself, not the amount of HER2 on the surface, is what matters for selecting patients.
The lung inflammation that came with it
Severe drug-related side effects — grade 3 or higher — occurred in 46% of patients. The commonest was a drop in neutrophils, a type of white blood cell, in 19%.
The finding that changed practice was a different one. An independent committee adjudicated 26% of patients as having drug-related interstitial lung disease: inflammation and scarring in the lungs. Two people died of it.
That is roughly one in four patients with a serious lung complication, in a trial of people who already have lung cancer. It is why teams now watch for a new cough or breathlessness with real seriousness during this treatment.
What this study cannot tell you
- Whether the drug beats any alternative. There was no control group, so 55% is a description of what happened, not a comparison.
- Whether people live longer because of it. Overall survival of 17.8 months has nothing to be measured against here.
- What the right dose is. Everyone in this cohort received the same weight-based infusion dose, which was higher than the amount later approved in breast cancer. A single-arm trial at one dose cannot weigh that dose against a lower one.
- How reliable the numbers are. 91 patients is a small base, and the confidence interval around the response rate runs from 44% to 65%.
Questions if a HER2 mutation is found in lung cancer
- Was this a HER2 mutation, or extra copies of the gene? They are not the same finding.
- What breathing symptoms should make me call you the same day?
- How often will my lungs be scanned while I am on this?
Sources
This article was written from the sources below, which were checked on the source-check date shown above.
How this article was prepared
Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.
Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.
Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Lung cancer. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.